Investing.com -- Cassava Sciences, Inc. (NASDAQ: SAVA )宣布获得其候选药物simufilam的一项治疗方法专利独家许可后，公司股价上涨7%。该专利涉及罕见神经发育障碍相关癫痫的潜在治疗方法，包括结节性硬化症（TSC）。

Shares of Cassava Sciences, Inc. (NASDAQ: SAVA) climbed 7% following the company’s announcement of securing an exclusive license to a method of treatment patent for its drug candidate, simufilam. The ...

Concurrent $3.5 Million Capital Raise With Second Contingent Tranche of $4.5 Million ...

Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an ...

Take two at bedtime. That’s what the label on the side of the bottle says, and that’s what you’ll do. You want to feel better soon — your health and well-being are important — so you’ll do as you’re ...

Cassava Sciences SAVA, a clinical-stage biotech focusing on developing novel products to detect and treat neurodegenerative ...

Doctored: Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s” by Charles Piller Will this affect your life? How?

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Cassava's leading drug candidate, simufilam. Defendants' statements included, among other ...

Cassava Sciences, a Texas biopharma company, had developed simufilam to treat (and possibly cure) Alzheimer’s disease, the most common form of dementia that afflicts tens of millions of people ...

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Cassava's leading drug candidate, simufilam. Defendants' statements included, among other ...

NEW YORK, Feb. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the ...